Clot removal distal protection methods

Information

  • Patent Grant
  • 11406404
  • Patent Number
    11,406,404
  • Date Filed
    Thursday, February 20, 2020
    5 years ago
  • Date Issued
    Tuesday, August 9, 2022
    2 years ago
Abstract
Provided herein are methods for protecting distal vessels from emboli during aspiration, the method comprising delivery and deployment of an emboli protection device which is advanced and placed distally relative to the clot burden and thus deep in the neurovascular bed until the device, once deployed, fully opposes a vessel wall creating a circumferential seal across the vessel. The methods utilizing the emboli protection device protect distal vasculature from vulnerable clot emboli which become dislodged during clot removal and/or aspiration and trapped in the emboli protection device.
Description
FIELD OF THE INVENTION

The invention disclosed herein relates generally to the field of clot removal protection devices and/or clot removal protection device systems and/or implantable devices for the use of clot removal protection.


BACKGROUND OF THE DISCLOSURE

There is a significant demand for the development of emboli protection devices for safer removal of clot material in patients suffering from an ischemic stroke event. Currently there is an unmet need for such devices which would provide a means of offering a protection barrier while preventing clinical sequelae that may lead to longer term morbidity and long-term patient rehabilitation. Safer removal of a clot contributes to a reduction in healthcare costs associated with treating patients impacted by ischemic stroke. While proximal protection devices are used in carotid arteries, no such devices are capable of offering protection deeper in the neurovascular bed, particularly for delivery distally in the brain.


Therefore, the invention methods disclosed herein adapt an implantable device design used for aneurysm and vessel occlusion treatment to an innovative treatment technique for deep brain and/or vessel embolic protection. See aneurysm treatment/occlusion device in U.S. Pat. No. 10,130,372, incorporated herein by reference in its entirety.


All documents and references cited herein and in the referenced patent documents, are hereby incorporated herein by reference.


SUMMARY OF THE INVENTION

Disclosed herein is a method for protecting distal vessels from emboli that dislodged during clot aspiration or mechanical thrombectomy using an emboli protection device which functions as a mesh shield thereby trapping emboli which can be retrieved and removed through an aspirating catheter.


In one embodiment, the method for protecting distal vessels from emboli comprises advancing an aspiration catheter to a position proximal to a clot burden, delivering through the aspiration catheter a microcatheter over a guidewire through to the distal end of a clot burden in a vessel to be treated, removing the guidewire, delivering and deploying an emboli protection device via an exchange length delivery wire through the microcatheter and placing the deployed device distal to the clot burden until it fully opposes the vessel wall creating a circumferential seal across the vessel, removing the microcatheter and leaving the emboli protection device and the exchange length delivery wire in place in the vessel, loading an aspiration catheter over the exchange length delivery wire and advancing the aspiration catheter proximal to the clot burden, commencing aspiration of the clot, whereby aspiration causes vulnerable clot emboli to become dislodged and trapped in the emboli protection device.


In one embodiment of the method disclosed herein, an emboli protection device is an implantable device comprising: (a) a substantially solid marker having a proximal end, and a distal end; and (b) a resilient mesh body attached to the distal end of the marker, the body having a delivery shape and a deployed shape capable of conforming to vessel walls; wherein the body is a dual layer of resilient mesh folded over onto itself to create a circumferential fold line around the circumference of the body, and folded over ends of the resilient mesh, and wherein all of the folded over ends of the dual layer of mesh are within the marker.


In another embodiment, the substantially solid marker is attached to an exchange length delivery wire. In one embodiment, the marker cannot be detached from the exchange length delivery wire. i.e. is permanently attached to the delivery wire.


In further embodiments, of the method disclosed herein, additional or varied steps include, without limitation, advancing the aspiration catheter through the clot, using a guidewire inside the aspiration catheter to navigate a large bore lumen device into position, and/or pulling back/while removing the emboli protection device and continuing to aspirate, whereby ensuring all trapped emboli are safely removed from the vessel.


In another embodiment of the method disclosed herein, an emboli protection device is an implantable device comprising: (a) a substantially solid marker having a proximal end, and a distal end; and (b) a resilient mesh body attached to the distal end of the marker, the body having a delivery shape and a deployed shape capable of conforming to vessel walls; wherein the body has a diameter greater than a diameter of a vessel to be treated. In another embodiment, the resilient mesh body has a low profile height to width ratio. In another embodiment, the height of the resilient mesh body is between about 10-20% of its width.


In another embodiment, the resilient mesh body of the device is a dual or double layer mesh. In a further embodiment, the dual layer of mesh comprises a single layer of mesh folded circumferentially.


In another embodiment, the proximal end of the marker of the emboli protection device is attached to an exchange length delivery wire.


In further embodiments, the marker is a radiopaque marker, the marker comprises a rigid member, and/or the marker is a solid ring.


Also disclosed herein is a kit comprising the emboli protection device disclosed herein and a delivery means for deploying the device.


In other embodiments, the device in the preceding paragraphs may incorporate any of the preceding or subsequently disclosed embodiments.


The Summary of the Invention is not intended to define the claims nor is it intended to limit the scope of the invention in any manner.


Other features and advantages of the invention will be apparent from the following Drawings, Detailed Description, and the Claims.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 illustrates a perspective view of an embodiment of the clot removal protection device disclosed herein and shows a low profile capability of the device relative to its diameter and height in free air.



FIG. 2 illustrates a cross section perspective view of an embodiment of the clot removal protection device and shows both the embodiment of the ends of the dual layer of resilient mesh ending in the marker and the embodiment of the dovetail end of the exchange delivery inside the marker.



FIG. 3 illustrates a perspective view of an embodiment of an embolic protection method disclosed herein and shows advancement of an aspiration catheter for placement proximal to the clot burden and then the advancement of a microcatheter and a guidewire through the aspiration catheter located proximal to the clot burden and continuing advancement of the microcatheter through the clot burden to a distal position relative to the clot burden.



FIG. 4 illustrates a perspective view of an embodiment of an embolic protection method disclosed herein and shows the guidewire removal and the emboli protection device delivery advancement through the microcatheter to a location distal to the clot burden.



FIG. 5 illustrates a perspective view of an embodiment of an embolic protection method disclosed herein and shows the emboli protection device deployment distal to the clot burden as it begins to open and oppose the vessel wall to create a circumferential seal across the vessel.



FIG. 6 illustrates a perspective view of an embodiment of an embolic protection method disclosed herein and shows the removal of the microcatheter over the exchange delivery wire leaving the emboli protection device (attached to the exchange delivery wire) in place in a distal location to the clot burden.



FIG. 7 illustrates a perspective view of an embodiment of an embolic protection method disclosed herein and shows the aspiration catheter in a location proximal to the clot burden for the commencement of aspiration.



FIG. 8 illustrates a perspective view of an embodiment of an embolic protection method disclosed herein and shows the clot burden being aspirated while vulnerable clot emboli become dislodged and trapped in the emboli protection device.



FIG. 9 illustrates a perspective view of an embodiment of an embolic protection method disclosed herein and shows continuation of the aspiration of the clot burden and emboli while vulnerable clot emboli become dislodged and trapped in the emboli protection device.



FIG. 10 illustrates a perspective view of an embodiment of an embolic protection method disclosed herein and shows the combination of pulling the emboli protection device back inside the aspiration catheter while continuing to aspirate for the purpose of ensuring all trapped emboli are safely removed from the vessel.





DETAILED DESCRIPTION

The invention disclosed herein is illustrated in the drawings and description in which like elements are assigned the same reference numerals. However, while particular embodiments are illustrated in the drawings, there is no intention to limit the invention to the specific embodiment or embodiments disclosed. Rather, the invention disclosed herein is intended to cover all modifications, alternative constructions, and equivalents falling within the spirit and scope of the invention. As such, the drawings are intended to be illustrative and not restrictive.


Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this technology belongs.


Exemplary embodiments of the invention disclosed herein are depicted in FIGS. 1-10.


Exemplary embodiments of the invention disclosed herein and in FIGS. 1-10 are as follows:



15: device in delivery shape



20: device in deployed shape



26: circumferential fold line



28: coil wound core of EDW



30: dual layer resilient mesh



32: height of mesh



40: vessel



50: marker



60: clot burden



70: microcatheter



80: guidewire



90: aspiration catheter



100: embolic material



110: exchange delivery wire



120: dovetail portion of exchange delivery wire


For the purposes of the invention disclosed herein, the terminology “corresponds to” means there is a functional and/or mechanical relationship between objects which correspond to each other. For example, an embolic protection device delivery system corresponds to (or is compatible with) an embolic protection device for delivery and deployment thereof.


For the purposes of the invention disclosed herein, the terminology “emboli protection device” or “distal protection device” means and/or may be interchangeable with terminology such as, without limitation, “device” or “device system” or “device implant” or “implant” and the like.


As disclosed herein the term “low profile” means that the resilient mesh body, in free air, has a height that is between about 10-20% of its width.


The invention disclosed herein is a method of protecting vessels distal or downstream of a clot (60) obstruction while the clot (60) is being removed from the brain or in a vessel (40) elsewhere in the body. Typically, as a clot is removed by either mechanical thrombectomy or aspiration, small fragments of clot can dislodge and travel downstream causing further obstruction and clinical sequelae. The invention disclosed herein utilizes a emboli protection device (15) as disclosed herein which is delivered and deployed (20) distal to the clot burden (60) by navigating a small catheter (70) through the clot burden (60) in the vessel (40) with minimal disruption to the clot (60). As the clot burden (60) is being removed, the deployed device (20) functions to protect the distal vessels from the risk of vulnerable embolic material (100) dislodged from the clot burden (60). The emboli protection device (20) is constructed with a double (or dual) layer of resilient mesh (30) which opens into a cup-like structure in which the resilient mesh opposes the vessel (40) circumferentially, thereby trapping any dislodged clot debris (100) during aspiration of the clot burden (60) or, alternatively, during mechanical thrombectomy. Once the clot burden (60) has been removed, the device (20) comprising trapped debris (100) in the device's resilient mesh body, is pulled back (away from or in the opposite direction of the distal vasculature) to the opening of the aspiration catheter (90) so that the trapped debris (100) gets aspirated at the same time the device is being pulled into the catheter (90) lumen.


Disclosed herein is a method for protecting distal vessels from emboli (100) that dislodged during clot aspiration using a device (20) which functions as a mesh shield thereby trapping emboli (100) which can be retrieved and removed through an aspirating catheter (90). The methods disclosed herein utilize a device (20) which is constructed from a woven resilient mesh material, the ends of which originate and terminate within a substantially solid marker, such as a radiopaque marker, at which point, affixed thereto is an exchange length delivery wire (110) for advancement of the device to a target site.


The invention method disclosed herein requires the use of an emboli protection device (20) whose body is comprised of resilient mesh folded (back onto itself) circumferentially in such as manner so as to create a mesh shield for trapping and removing any and all vulnerable emboli (100) from a vessel (40) comprising a clot burden (60). In one embodiment, the emboli protection device (20) body is a dual layer of resilient mesh (30) folded over onto itself to create a circumferential fold line around the circumference of the body, and folded over ends of the resilient mesh, and wherein all of the folded over ends of the dual layer of mesh are within the marker. See aneurysm treatment/occlusion device in U.S. Pat. No. 10,130,372, incorporated herein by reference in its entirety.


In one embodiment, the method for protecting distal vessels from emboli comprises a) advancing an aspiration catheter to a position proximal to a clot burden and delivering through the aspiration catheter a microcatheter (70) over a guidewire (80) through to the distal end of a clot burden (60) in a vessel (40) to be treated, b) removing the guidewire (80), c) delivering and deploying an emboli protection device (20) through the microcatheter (70) and placing the device (20) distal to the clot burden (60) until it fully opposes the vessel (40) wall creating a circumferential seal across the vessel (40), wherein the emboli protection device (20) is attached to an exchange length delivery wire (110), d) removing the microcatheter (70) and leaving the emboli protection device (20) and the exchange length delivery wire (110) in place in a distal location to the clot burden (40), e) commencing aspiration of the clot (60), whereby aspiration causes vulnerable clot emboli (100) to become dislodged and trapped in the emboli protection device (20).


In another embodiment, the method for protecting distal vessels from emboli comprises additional or varied steps which include, without limitation, g) advancing the aspiration catheter (90) through the clot (60), h) using a guidewire (80) inside the aspiration catheter (90) to navigate a large bore lumen device into position, and/or i) pulling back/while removing the emboli protection device (20) and continuing to aspirate, whereby ensuring all trapped emboli (100) are safely removed from the vessel (40).


In one embodiment of the emboli protection device (20) disclosed herein, the position of the distal end of the substantially solid marker (50) is attached approximately centrally on the underside of the resilient mesh body, that is, the marker (50) opposes the folded over mesh at the top side of the device (20). Such a positioning of the marker on the mesh body confers full connection capability to the exchange length delivery wire (110) of the device (20) used in the methods disclosed herein. In one embodiment, the device (20) cannot be detached from the exchange delivery wire (110) because the exchange delivery wire (110) is attached to the device via its dovetail portion (120) residing within the marker (50). See FIG. 2. In another embodiment, all the folded over ends of the resilient mesh are within the marker (50). See FIG. 2. In another embodiment, all the folded over ends of the dual layer of resilient mesh (30) originate and terminate in the marker (50). See FIG. 2. In another embodiment, the emboli protection device (20) used herein is “oversized” relative to a vessel (40) comprising a clot burden (60) to be treated. In this instance, the diameter (x) of the device (20) is greater than the diameter of any vessel (40) containing a clot burden (60) to be treated so long as the body of the device (20) is capable of conforming to vessel (40) walls by opposing the vessel (40) walls to create a circumferential seal across the vessel (40).


In one embodiment, the emboli protection device (20) disclosed herein is constructed of DFT Nitinol (NiTi) (DFT=Drawn Filled Tubing) to permit recovery of the device to its preformed disc like configuration, ensuring that when it is deployed it expands to oppose the vessel (40) circumferentially thereby trapping any vulnerable and dislodged clot debris (100). In one embodiment, the number of wires of the device construction ranges from 24 to 32 wire ends, double backed on each other to create a double layer of resilient mesh to give the equivalent of 48 to 64 strands in the resilient mesh body of the device. In one embodiment, the body of the device is relatively flat or curved to create a cup like appearance in the vessel (40) and this confers a protective barrier once the device (20) opposes the vessel (40) wall.


In one embodiment, the embolic protection device (20) disclosed herein is the vessel implantation device disclosed in U.S. Pat. No. 10,130,372, incorporated herein by reference in its entirety. In another embodiment, the device disclosed herein is similar to the vessel implantation device disclosed in U.S. Pat. No. 10,130,372, except the device used herein for protecting distal vessels from dislodged emboli (100) does not have a detachment point between the device marker (50) and the end of the exchange delivery wire (110). Instead, the device (20) is attached and cannot be detached from the exchange delivery wire (110). In one embodiment, the device (20) cannot be detached from the exchange delivery wire (110) because the exchange delivery wire (110) is attached to the device via its dovetail portion (120) residing within the marker (50). In one embodiment, the exchange delivery wire has a diameter of about 0.014 inches. The appropriate diameter is determined to ensure sufficient bond strength between the device (20) and the exchange delivery wire (110) as it is being retrieved inside the aspiration catheter (90) in the final steps of the methods disclosed herein.


The methods disclosed herein provide protection deeper in the neurovascular bed (that is, for example, deeper into the brain in the more distal vasculature beyond the clot burden) because of the unique construction of the emboli protection device (20) for use in the methods but additionally because of the distal placement of the device in relation to the clot burden (60). The emboli protection device (20) disclosed herein is scalable to treat larger vessels and its particular construction of resilient mesh with ends originating and terminating in the marker (50), combined with its low profile delivery (15) and deployment (20) shapes, uniquely confer the capability to be delivered deeper distally in the brain into the distal vasculature beyond the clot burden. In particular, the device (20) disclosed herein is flexible enough to conform to vessels (40) of varying diameters ranging from as small as about 2.5 mm up to about 4 mm in diameter.


For the purposes of the emboli protection device (20) and methods of use disclosed herein, the terminology “low profile” means that the resilient mesh body, in free air, has a height (32) that is between about 10-20% of its width, and therefore in its deployed shape the resilient mesh body of the device (20) is capable of conforming to vessel (40) walls by opposing the vessel (40) walls to create a circumferential seal across the vessel (40). In another embodiment of the device (20) used in the methods disclosed herein, the single layer or dual layer (30) of resilient mesh material of the device comprises a relatively uniform distribution of wire mesh strands or braids such as, without limitation, a 32 nitinol (NiTi) wire mesh strand braided configuration. In other embodiments, the device comprises wire mesh strands or braids that range from 24 to 64 NiTi strand braided configuration. In another embodiment, the number of wires of the device construction ranges from 24 to 32 wire ends, double backed on each other to create a double layer of resilient mesh to give the equivalent of 48 to 64 strands in the resilient mesh body of the device. In one embodiment, the body of the device is relatively flat or curved to create a cup like appearance in the vessel (40) and this confers a protective barrier once the device (20) opposes the vessel (40) wall.


In another embodiment, an embolic protection device (20) disclosed herein is a configuration of wire mesh which is folded circumferentially (circumferential fold line (26)) and therefore doubled back on itself to create a dual layer of resilient mesh (30). The ends of the dual or doubled back layer (30) intersect with the marker (50) positioned approximately at the core of the body of the device (20). In this regard, the device is constructed by circumferentially folding a single layer of mesh material over itself on a preferential (or circumferential) fold line effectively resulting in a device (20) comprising a dual layer (30) of wire mesh material, i.e., the dual layer of mesh (30) comprises a single layer of mesh folded circumferentially (circumferential fold line (26)). The doubled or dual layer (30) of wire mesh material contributes to the enhanced acute thrombogenicity of the device (20) in prior animal studies. It is also believed that this provides the device (20) with the capability, once deployed deep in the vasculature and distal to the clot burden (60), to fully oppose the vessel (40) wall creating a circumferential seal across the vessel (40).


In its low-profile deployed shape (20), the resilient mesh body, having a double backed dual layer (30) combined with its placement deeper in the vasculature when compared to a non-deployed (15) doubled back dual layer of resilient mesh accounts for a change in width of approximately 15% which translates to an increase in the diameter (x) of the device (20) when pressure is applied at the marker (50). This change in width/increase in diameter (x) is an effective anchoring feature of the deployed device (20) as blood applies pressure to the mesh body distributed across the vessel (40). Such a configuration also provides sufficient apposition of the mesh body of the device (20) against the vessel (40) wall.



FIGS. 1-10 show the position of the marker (50), having a proximal end and a distal end, on an emboli protection device (20) of the invention disclosed herein. In one embodiment, the distal end of the marker (50) is attached to the resilient mesh body of the emboli protection device (15, 20). In another embodiment, the proximal end of the marker (50) is affixed to and cannot be detached from the exchange length delivery wire (110). In another embodiment, the exchange delivery wire (110) is attached or affixed to the device (20) by a dovetail portion (120) end of the exchange delivery wire (110).


In one embodiment, the marker (50) of the device disclosed herein is a substantially solid collar or rigid member such as, without limitation a solid ring comprised of materials such as, without limitation, gold, platinum, stainless steel, and/or combinations thereof. In another embodiment, radiopaque materials such as, without limitation, gold, platinum, platinum/iridium alloy, and/or combinations thereof, can be used. Such a marker (50) provides visualization of the device (20) during delivery and placement. In one embodiment, the marker (50) is positioned centrally within the device (20) so that the proximal end of the marker (50) is connected to the exchange length delivery wire (110). The solid construction of the marker (50) helps confer stability to the device (20) within the vessel (40) and prevents movement or the transfer of forces through the resilient mesh body thereby preventing misplacement or accidental movement of the device (20). In one embodiment, the marker (50) is configured with a junction to cooperate and release from/attach or connect to a suitable corresponding delivery means such as, without limitation, a delivery microcatheter (70), catheter, exchange length delivery wire (110), guide wire (80) and/or pusher wire technologies.


In another embodiment, the substantially solid marker (50) comprises a radiopaque material (such as for example, without limitation, platinum, gold, platinum/iridium alloy, and/or combinations thereof) to facilitate visualization of the device (20) under fluoroscopy during delivery, placement and/or deployment. The marker (50) comprises a proximal end and a distal end. A resilient mesh body is attached to the distal end and the proximal end of the marker (50) may be configured to influence shape, diameter, and/or curvature of the resilient mesh body upon expansion of the device (20) disclosed herein. The marker (50) may be designed in various shapes to influence the overall profile of the emboli protection device (20) to ensure a proper fit of the expanded/deployed device (20) within the vessel (40).



FIGS. 2-10 show an exemplary method for delivery and/or deployment, through a clot burden within a vessel. In one embodiment, the device (15) is delivered in a closed, compacted position (delivery shape) as shown in FIGS. 3 and 4, such that the low profile resilient mesh body is closed inward on itself or compressed, via a pusher wire mechanism in a microcatheter (70). When the device (20) is pushed into and/or placed in a distal location relative to the clot burden (60), the ends of the low profile resilient mesh body open outward in the manner of the opening of a cup-like configuration with the cup's open end facing opposite or away from the clot (60) (as shown in FIGS. 5-9) and the opened body then conforms to the walls of the vessel (40) and fully opposes the vessel walls creating a circumferential seal across the vessel (40). In one embodiment, as shown in FIGS. 6-8, the device (20) comprising its dual layer of resilient mesh (30) is capable of deepening or increasing its depth accounting for a change in width and an increase in the diameter of the device (20) when pressure is applied at the marker (50). This change in width/increase in diameter is an effective anchoring feature of the deployed device (20) as blood applies pressure to the resilient mesh (30) body distributed across and sealing the vessel (40) distal to the clot burden (60). Results of animal studies provided herein support that the circumferential seal created by the cup-like configuration of the dual layer of resilient mesh (30) provides efficient apposition of the mesh body against the vessel (40) wall.


In other embodiments, the device (20) disclosed herein may further incorporate separate or combined adjunctive elements and/or members such as coiling techniques, framing coils, embolic agents, additional markers, polymers, resorbent polymers and/or a combination thereof.


Resilient mesh materials for design and/or manufacture of the device disclosed herein are readily available and well known by those skilled in the relevant art. As such, resilient mesh materials range from a wide variety of available materials such as, without limitation, nickel titanium (nitinol or otherwise known as NiTi), stainless steel, polymers, and/or combinations thereof. Exemplary known biomedical polymeric families include, without limitation, polymers such as polyphosphazenes, polyanhydrides, polyacetals, poly(ortho esters), polyphosphoesters, polycaprolactones, polyurethanes, polylactides, polycarbonates, polyamides, and/or a combination thereof. (See, e.g., J Polym Sci B Polym Phys. Author manuscript; available in PMC 2012 Jun. 15.)


In one exemplary embodiment, the resilient mesh material is formed of woven strands of polymer material, such as, without limitation, nylon, polypropylene or polyester. The polymer strands can be filled with a radiopaque material which allows the physician treating the aneurysm to fluoroscopically visualize the location of the device within the vasculature. Radiopaque filler materials preferably include bismuth trioxide, tungsten, titanium dioxide or barium sulfate, or radiopaque dyes such as iodine. The resilient mesh material can be formed by strands of radiopaque material. The radiopaque strands allow the physician and/or radiologist to fluoroscopically visualize the location of the mesh, without the use of filled polymer materials. Such radiopaque strands may be formed with materials such as, without limitation, gold, platinum, a platinum/iridium alloy, and/or a combination thereof. In one embodiment, the resilient mesh material is constructed of 10%-20% platinum core NiTi. In another embodiment, the resilient mesh material is constructed of 10% platinum core NiTi, 15% platinum core NiTi, or 20% platinum core NiTi. 10% platinum core NiTi construction is sufficient to provide a ghost image of the device under x-ray.


Such constructed combination wires or composite wires having a radiopaque core and non-radiopaque outer layer or casing are readily available and well known in the medical device and metallic arts as DFT® (drawn-filled-tube) wires, cables or ribbons. DFT® wire is a metal-to-metal composite constructed to combine the desired physical and mechanical attributes of two or more materials into a single wire. By placing the more radiopaque, but more ductile material in the core of the wire, the NiTi outer layer is able to provide the resulting composite wire with similar mechanical properties of a 100% NiTi wire. DFT® wires are available from Fort Wayne Metals Corp., Fort Wayne, Ind., U.S.A. See also, for example, the journal article entitled Biocompatible Wire by Schaffer in Advanced Materials & Processes, October 2002, pages 51-54, incorporated herein by reference.


Where the resilient mesh material is formed of radiopaque metal strands, the strands may be covered with a polymer coating or extrusion. The coating or extrusion over the radiopaque wire strands provides fluoroscopic visualization but also increases the resistance of the strands to bending fatigue and may also increase lubricity of the strands. The polymer coating or extrusion, in one embodiment, is coated or treated with an agent which tends to resist clotting, such as heparin. Such clot resistant coatings are generally known. The polymer coating or extrusion can be any suitable extrudable polymer, or any polymer that can be applied in a thin coating, such as Teflon® or polyurethane.


In yet another embodiment, the strands of the resilient mesh material are formed using both metal and polymer braided strands. Combining the metal strands with the polymer strands into a braid changes the flexibility characteristics of mesh. The force required to deploy and/or collapse such a mesh portion is significantly reduced over that required for a mesh portion that includes only metal mesh strands. However, the radiopaque characteristics of the mesh for fluoroscopic visualization are retained. Metal strands forming such a device includes, without limitation, stainless steel, gold, platinum, platinum/iridium, nitinol, and/or combinations thereof. Polymer strands forming the device can include nylon, polypropylene, polyester, Teflon®, and/or combinations thereof. Further, polymer strands of the mesh material can be chemically modified to make them radiopaque with known techniques such as, without limitation, by using gold deposition onto the polymer strands, or by using ion beam plasma deposition of suitable metal ions onto the polymer strands.


The resilient mesh material can also be formed with filaments or strands of varying diameter and/or varying flexibility. By varying the size or flexibility of the polymer strands, the flexibility characteristics of the mesh, upon deployment, can also be varied. By varying the flexibility characteristics, both the deployed and collapsed configuration of the resilient mesh body can be varied or changed to substantially any desired shape.


Not only can the mesh be formed of both polymer strands or filaments and metal strands or filaments, but it can be formed using filaments of different polymer materials. For example, different polymer materials having different flexibility characteristics can be used in forming the mesh. This alters the flexibility characteristics to change the resultant configuration of the mesh body in both the deployed and the collapsed positions. Such biomedical polymers are readily known and available in the art and can be derived from polymeric families such as, without limitation, polyphosphazenes, polyanhydrides, polyacetals, poly (ortho esters), polyphosphoesters, polycaprolactones, polyurethanes, polylactides, polycarbonates, polyamides, and/or a combination thereof.


Resilient mesh materials suitable for use within the mesh body may take the form of a flat woven sheet, knitted sheet, or a laser cut wire mesh. In general, the material should include two or more sets of substantially parallel strands, with one set of parallel strands being at a pitch of between 45 degrees and 135 degrees with respect to the other set of parallel strands. In some embodiments, the two sets of parallel strands forming the mesh material are substantially perpendicular to each other. The pitch and general construction of the mesh material may be optimized to meet the performance needs of the device.


The wire strands of the metal fabric used in the invention disclosed herein should be formed of a material which is both resilient and can be heat-treated to substantially set a desired shape. Materials which are believed to be suitable for this purpose include a cobalt-based low thermal expansion alloy referred to in the field of medical devices as Elgiloy®, nickel-based high-temperature high-strength “superalloys” commercially available from Haynes International under the trade name Hastelloy®, nickel-based heat treatable alloys sold under the name Incoloy® by International Nickel, and a number of different grades of stainless steel. The important factor in choosing a suitable material for the wires is that the wires retain a suitable amount of the deformation induced by the molding surface (or shape memory, as described below) when subjected to a predetermined heat treatment.


One class of materials which meet these qualifications are so-called shape memory alloys. Such alloys tend to have a temperature induced phase change which will cause the material to have a preferred configuration which can be fixed by heating the material above a certain transition temperature to induce a change in the phase of the material. When the alloy is cooled, the alloy will “remember” the shape it was in during the heat treatment and will tend to assume that same and/or similar configuration unless constrained from doing so.


One particular shape memory alloy for use in the invention disclosed herein is nitinol, an approximately stoichiometric alloy of nickel and titanium, which may also include other minor amounts of other metals to achieve desired properties. NiTi alloys such as nitinol, including appropriate compositions and handling requirements, are well known in the art and such alloys need not be discussed in detail here. For example, U.S. Pat. Nos. 5,067,489 and 4,991,602, the teachings of which are incorporated herein by reference, discuss the use of shape memory NiTi alloys in guide wire-based technologies. Such NiTi alloys are preferred, at least in part, because they are commercially available and more is known about handling such alloys than other known shape memory alloys. NiTi alloys are also very elastic. Indeed, they are said to be known as “superelastic” or “pseudoelastic.” This elasticity will help an emboli protection device (20) as disclosed herein return to prior expanded configuration for deployment thereof.


In some embodiments, the wire strands comprise a standard monofilament of the selected material, i.e., a standard wire stock is used. In some embodiments, 24 wire strands and/or 24 strand braid configurations are used. In other embodiments, the device comprises wire mesh strands or braids that range from 24 to 48 NiTi strand braided configurations. If so desired, though, the individual wire strands may be formed from “cables” made up of a plurality of individual wires. For example, cables formed of metal wires where several wires are helically wrapped about a central wire are commercially available and NiTi cables having an outer diameter of 0.003 inches or less can be purchased. One advantage of certain cables is that they tend to be “softer” than the monofilament wires having the same diameter and formed of same material. Additionally, the use of a cable increases the effective surface area of the wire strand, which will tend to promote thrombosis.


An emboli protection device (20) disclosed herein is configured with low profile resilient mesh material of a mesh density sufficient for functioning in such a manner as an endothelial cell scaffold within a vessel. For the purposes of the invention disclosed herein, the terminology “mesh density” means the level of porosity or the ratio of metal to open area of the mesh body. Mesh density relates to the number and size of the openings or pores of the mesh and by the extent that the pores are open or closed in situations where opening or pore openness varies between delivery and deployment. Generally, a high mesh density region of a resilient mesh material has approximately about 40% or more metal area and about 60% or less open area.


In some embodiments, the resilient mesh body of the device (20) is formed uniformly of the same material; however such material may have different knitted, stitched, braided, and/or cut construction.


The principal use of aspiration catheters is to remove a thrombus that forms in a patient's arteries to prevent obstruction of the blood vessel in which the thrombus has formed due to a stroke or blockage. Aspiration catheters (90) used in the distal protection methods herein are readily available in the art. Aspiration catheters (90) usually consist of an over the wire single lumen system with a distal radiopaque tip marker and a proximal luer lock port attached to a syringe for hand-powered suction or a mechanical/aspiration pump to remove a thrombus. The catheter further includes an aspiration port to which a source of negative pressure is attached. In one embodiment, the aspiration catheter (90) is approximately 95-135 cm in length. Suction in aspiration catheters can be provided by an apparatus such as a pump, e.g., a vacuum pump, or a syringe. In some embodiments, the aspiration catheter (90) is a large bore aspiration catheter. In some embodiments, the aspiration catheter (90) is an aspiration pump. An aspiration catheter used in the distal protection methods disclosed herein is an aspiration catheter of a standard size. Radiopaque markers can be located at the distal ends of the catheters to assist in positioning the catheter within the body. Aspiration catheters are generally constructed with varying flexibility along the length of the shaft such that they are sufficiently flexible to be steered through the patient's vasculature without causing damage, but retain adequate stiffness to enable the axial push needed to place the catheter in the proper location and to withstand the aspiration pressures. Aspiration catheters used herein may vary in size, typically ranging from 5 thru 8 French (Fr.) (1 Fr.=0.013 inches). (As is well known in the art, the French scale or French gauge system is commonly used to measure the size of a catheter.)


Microcatheters (70) used herein are typically standard in sizing and readily available in the art. For example, microcatheter profiles such as the commonly used, 017 (internal diameter 17/1000s inch), and the 021 are well known and readily available. In certain embodiments, a 017 microcatheter is small enough that when you advance it thru the clot burden (60) the clinician (or operator) creates minimal disturbance of the clot (60)—i.e., prevents disturbance of the clot burden (60). Microcatheters used herein are selected based upon criteria such as anatomy, vessel size, pressure variances, capability to preclude trauma, and system compatibility.


The device (20) and methods disclosed herein may incorporate reasonable design parameters, features, modifications, advantages, and variations that are readily apparent to those skilled in the art in the field of medical devices.


EXAMPLES

An animal study was conducted to evaluate the mechanics of the procedure and the interaction of the device with other devices used in the clot aspiration procedure. The study was conducted in the Research Institute of Neurointervention, Animal Lab, Salzburg, Austria under supervision of a veterinarian and experienced Neurointerventional Radiologists.


Clot doped with Tantalum for ease of visualization was prepared and introduced into the animal vasculature.


The first step of the clot removal distal protection procedure was to advance nn 0.014″ guidewire through the clot burden, followed by advancing the microcatheter to the distal end of the clot. The microcatheter was then strategically positioned to deploy the embolic protection device distal to the clot burden. Accordingly, the embolic protection device was advanced through the microcatheter and deployed distal to the clot burden. With the device successfully deployed and the microcatheter in place, the aspiration catheter was advanced over the microcatheter into position proximal to the clot burden. The microcatheter was then removed over the exchange length wire of the embolic protection device prior to aspirating the clot.


The clot was successfully aspirated via two methods:


The distal protection device remained in place while the clot was being aspirated and the aspiration catheter was advanced up to the device and finally pulled inside the lumen removing all collected emboli that dislodged during aspiration.


After approximately 50% of the clot burden was aspirated, the operator pulled the distal protection device proximally, pulling the remaining clot burden inside the aspiration catheter while still applying suction.


The device used in this study was delivered through an 021 microcatheter, similar to what stentrievers are delivered through for mechanical thrombectomy. The optimal device configurations are variable according to each patient to be treated. In one embodiment, the distal protection device is delivered through an even smaller, e.g., 017, microcatheter to minimize the disturbance of the clot burden when advancing through the distal end of the clot to deploy the device. In another embodiment, the device is be constructed with 48 wire strands of 0.001″ DFT Nitinol which will permit the operator to observe the device being successfully deployed and open beyond the clot.


In certain embodiments, the device configurations ranges in diameter from 2.5 to 4.5 mm and the size of the device will be selected depending on the size of the vessel it is being deployed into to offer good wall apposition and distal protection.


Manipulation and deployment control of the occlusion device were carried out while visualizing the proximal radiopaque marker of the device in relation to the catheter tip. Device development will entail the incorporation of radiopaque struts of platinum core NiTi wire to aid in visibility.


Device manipulation and deployment was easy to manipulate with pinpoint accuracy, particularly in relation to guidance through the vessels and the clot burden as well as placement of the device distal to the clot burden in the treated animals.


A number of embodiments of the invention have been described. Without departing from the scope and spirit of the invention disclosed herein, reasonable features, modifications, advantages, and design variations of the claimed apparatus will become readily apparent to those skilled in the art by following the guidelines set forth in the preceding detailed description and embodiments. Accordingly, other embodiments are within the scope of the following claims.

Claims
  • 1. A method for protecting distal vessels from dislodged emboli comprising: a. advancing an aspiration catheter proximal to clot burden,b. advancing a microcatheter and guidewire through the aspiration catheter through and distal to the clot burden in a vessel to be treated,c. removing the guidewire,d. deploying an emboli protection device comprising a resilient mesh body through the microcatheter and placing the device distal to the clot burden until it fully opposes the vessel wall thereby creating a circumferential seal across the vessel, wherein the emboli protection device is attached to an exchange length delivery wire, wherein the exchange length delivery wire comprises a dovetail portion end inside a marker of the device,e. removing the microcatheter and leaving the emboli protection device and the exchange length delivery wire in place in the vessel, andf. commencing aspiration of the clot, whereby aspiration causes vulnerable clot emboli to become dislodged and trapped in the emboli protection device.
  • 2. The method according to claim 1, wherein the emboli protection device is an implantable device comprising: a. the marker having a proximal end, and a distal end; andb. the resilient mesh body, wherein the resilient mesh body is attached to the distal end of the marker, wherein the resilient mesh body has a delivery shape and a deployed shape capable of conforming to vessel walls; wherein the resilient mesh body is a dual layer of resilient mesh folded over onto itself to create a circumferential fold line around the circumference of the body, and folded over ends of the resilient mesh, and wherein all of the folded over ends of the dual layer of mesh are within the marker.
  • 3. The method according to claim 2, wherein the marker is attached to the exchange length delivery wire.
  • 4. The method according to claim 1, further comprising g) advancing the aspiration catheter up to the clot as the aspiration catheter applies suction.
  • 5. The method according to claim 4, further comprising h) the combination of pulling back while removing the emboli protection device and continuing to aspirate, whereby ensuring all trapped emboli are safely removed from the vessel.
  • 6. The method according to claim 1, wherein the emboli protection device is an implantable device comprising: (a) the marker having a proximal end, and a distal end; and (b) the resilient mesh body attached to the distal end of the marker, the body having a delivery shape and a deployed shape capable of conforming to vessel walls; wherein the body has a diameter greater than a diameter of a vessel to be treated.
  • 7. The method according to claim 1, wherein the resilient mesh body of the device has a low profile height to width ratio.
  • 8. The method according to claim 7, wherein the resilient mesh body of the device has height that is between about 10-20% of its width.
  • 9. The method according to claim 1, wherein the resilient mesh body of the emboli protection device is a dual or double layer mesh.
  • 10. The method of claim 9, wherein the dual layer of mesh comprises a single layer of mesh folded circumferentially.
  • 11. The method according to claim 1, wherein the proximal end of the marker of the emboli protection device is attached to the exchange length delivery wire in such a manner wherein the emboli protection device cannot be detached from the exchange length delivery wire.
  • 12. The method according to claim 1, wherein the marker is a radiopaque marker.
  • 13. The method according to claim 1, wherein the marker comprises a rigid member.
  • 14. The method according to claim 1, wherein the marker is a solid ring.
  • 15. A method for removing a clot burden from a blood vessel comprising: a. advancing an aspiration catheter to a position proximal to the clot burden,b. advancing a microcatheter and guidewire to a position distal to the clot burden in a vessel to be treated,c. removing the guidewire,d. placing an emboli protection device comprising a resilient mesh body in position in a location distal to the clot burden and fully opposing the vessel wall to create a circumferential seal across the vessel, wherein the emboli protection device is attached to an exchange length delivery wire, wherein the exchange length delivery wire comprises a dovetail portion end inside a marker of the device,e. removing the microcatheter and leaving the emboli protection device in place in the vessel, andf. commencing aspiration of the clot burden.
  • 16. The method of claim 15, wherein the resilient mesh body of the device has height that is between about 10-20% of its width.
  • 17. The method of claim 15, wherein the resilient mesh body of the device is a dual or double layer mesh.
  • 18. The method according to claim 17, wherein the dual layer of mesh comprises a single layer of mesh folded circumferentially.
US Referenced Citations (424)
Number Name Date Kind
2849002 Oddo Aug 1958 A
3480017 Shute Nov 1969 A
4364392 Strother et al. Dec 1982 A
4395806 Wonder et al. Aug 1983 A
4545367 Tucci Oct 1985 A
4836204 Landymore et al. Jun 1989 A
4991602 Amplatz et al. Feb 1991 A
5002556 Ishida et al. Mar 1991 A
5025060 Yabuta et al. Jun 1991 A
5065772 Cox, Jr. Nov 1991 A
5067489 Lind Nov 1991 A
5122136 Guglielmi et al. Jun 1992 A
5192301 Kamiya et al. Mar 1993 A
5423829 Pham et al. Jun 1995 A
5496277 Termin et al. Mar 1996 A
5624449 Pham et al. Apr 1997 A
5733294 Forber et al. Mar 1998 A
5891128 Gia et al. Apr 1999 A
5928260 Chin et al. Jul 1999 A
6007573 Wallace et al. Dec 1999 A
6024756 Pham Feb 2000 A
6080191 Thaler Jun 2000 A
6096021 Helm et al. Aug 2000 A
6113609 Adams Sep 2000 A
6123714 Gia et al. Sep 2000 A
6152144 Lesh et al. Nov 2000 A
6168579 Tsugita Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6221086 Forber Apr 2001 B1
6270515 Linden et al. Aug 2001 B1
6315787 Tsugita et al. Nov 2001 B1
6334048 Edvardsson et al. Dec 2001 B1
6419686 McLeod et al. Jul 2002 B1
6454780 Wallace Sep 2002 B1
6463317 Kucharczyk et al. Oct 2002 B1
6506204 Mazzocchi Jan 2003 B2
6527919 Roth Mar 2003 B1
6547804 Porter et al. Apr 2003 B2
6551303 Tassel et al. Apr 2003 B1
6569190 Whalen, II et al. May 2003 B2
6589230 Gia et al. Jul 2003 B2
6589256 Forber Jul 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6620152 Guglielmi Sep 2003 B2
6663068 Huang Dec 2003 B2
6669719 Wallace et al. Dec 2003 B2
6669721 Bose et al. Dec 2003 B1
6689159 Lau et al. Feb 2004 B2
6780196 Chin et al. Aug 2004 B2
6811560 Jones Nov 2004 B2
6833003 Jones et al. Dec 2004 B2
6855154 Abdel-Gawwad Feb 2005 B2
6949116 Solymar et al. Sep 2005 B2
6953472 Palmer Oct 2005 B2
7044134 Khairkhahan et al. May 2006 B2
7093527 Rapaport et al. Aug 2006 B2
7128073 Burg et al. Oct 2006 B1
7128736 Abrams et al. Oct 2006 B1
7152605 Khairkhahan et al. Dec 2006 B2
7195636 Avellanet et al. Mar 2007 B2
7229454 Tran et al. Jun 2007 B2
7229461 Chin et al. Jun 2007 B2
7232461 Ramer Jun 2007 B2
7306622 Jones Dec 2007 B2
7371249 Douk et al. May 2008 B2
7410482 Murphey et al. Aug 2008 B2
7572288 Cox Aug 2009 B2
7597704 Frazier et al. Oct 2009 B2
7695488 Berenstein et al. Apr 2010 B2
7713264 Murphy May 2010 B2
7722641 Burg et al. May 2010 B2
7744652 Morsi Jun 2010 B2
7828818 Zang et al. Nov 2010 B2
7892254 Klint Feb 2011 B2
8034061 Amplatz et al. Oct 2011 B2
8066757 Ferrera Nov 2011 B2
8075585 Lee et al. Dec 2011 B2
8080032 Burg et al. Dec 2011 B2
8088140 Ferrera Jan 2012 B2
8142456 Rosqueta et al. Mar 2012 B2
8221483 Ford et al. Jul 2012 B2
8252040 Cox Aug 2012 B2
8261648 Marchand et al. Sep 2012 B1
8262692 Rudakov Sep 2012 B2
8267923 Murphy Sep 2012 B2
8361106 Solar et al. Jan 2013 B2
8361138 Adams Jan 2013 B2
8372114 Hines Feb 2013 B2
8398671 Chen Mar 2013 B2
8430012 Marchand et al. Apr 2013 B1
8454633 Amplatz et al. Jun 2013 B2
8470013 Duggal et al. Jun 2013 B2
8500751 Rudakov et al. Aug 2013 B2
8523897 Burg et al. Sep 2013 B2
8535343 Burg et al. Sep 2013 B2
8545514 Ferrera Oct 2013 B2
8562667 Cox Oct 2013 B2
8574262 Ferrera Nov 2013 B2
8585713 Ferrera Nov 2013 B2
8597320 Sepetka Dec 2013 B2
8663273 Khairkhahan Mar 2014 B2
8696701 Becking Apr 2014 B2
8715312 Burke May 2014 B2
8715316 Janardhan et al. May 2014 B1
8747453 Amplatz Jun 2014 B2
8771294 Sepetka Jul 2014 B2
8834519 Van Der Burg Sep 2014 B2
8926680 Ferrera Jan 2015 B2
8945172 Ferrera Feb 2015 B2
9034054 Gerberding May 2015 B2
9039724 Amplatz et al. May 2015 B2
9060077 Sayama Jun 2015 B2
9060777 Wallace Jun 2015 B1
9078658 Hewitt Jul 2015 B2
9107670 Hannes Aug 2015 B2
9138213 Amin Sep 2015 B2
9161758 Figulla Oct 2015 B2
9168043 Van Der Burg Oct 2015 B2
9179918 Levy Nov 2015 B2
9186487 Dubrul et al. Nov 2015 B2
9198668 Theobald Dec 2015 B2
9198670 Hewitt Dec 2015 B2
9198687 Fulkerson Dec 2015 B2
9220522 Fulkerson Dec 2015 B2
9259337 Cox Feb 2016 B2
9271736 Heipl Mar 2016 B2
9295473 Hewitt Mar 2016 B2
9307998 Chin Apr 2016 B2
9314326 Wallace Apr 2016 B2
9387098 Ferrera Jul 2016 B2
9474517 Amin Oct 2016 B2
9492174 Hewitt Nov 2016 B2
9498604 Dubrul Nov 2016 B2
9532772 Moszner Jan 2017 B2
9539122 Burke Jan 2017 B2
9545300 Cully Jan 2017 B2
9572698 Franano Feb 2017 B2
9597087 Marchand Mar 2017 B2
9622770 Trapp Apr 2017 B2
9629635 Hewitt Apr 2017 B2
9795400 Davidson Oct 2017 B2
9826980 Figulla Nov 2017 B2
9839430 Willems Dec 2017 B2
9861467 Cully Jan 2018 B2
9877726 Liu Jan 2018 B2
9918720 Marchand Mar 2018 B2
9943299 Khairkhahan Apr 2018 B2
9955976 Hewitt May 2018 B2
9962146 Hebert May 2018 B2
9980733 Badruddin May 2018 B2
10028745 Morsi Jul 2018 B2
10028747 Connor Jul 2018 B2
10076399 Davidson Sep 2018 B2
10123803 Ferrera et al. Nov 2018 B2
10130372 Griffin Nov 2018 B2
10136896 Hewitt et al. Nov 2018 B2
10159490 Wallace et al. Dec 2018 B2
10231722 Hebert et al. Mar 2019 B2
10238393 Marchand et al. Mar 2019 B2
10265075 Porter et al. Apr 2019 B2
10278705 Amin et al. May 2019 B2
10285678 Hebert et al. May 2019 B2
10285679 Hebert et al. May 2019 B2
10285711 Griffin May 2019 B2
10299775 Hebert et al. May 2019 B2
10342546 Sepetka et al. Jul 2019 B2
10383635 Wallace et al. Aug 2019 B2
10398441 Warner et al. Sep 2019 B2
10398444 Morsi Sep 2019 B2
10433851 Adams et al. Oct 2019 B2
10478194 Rhee et al. Nov 2019 B2
10499939 Davidson Dec 2019 B2
10537451 Franano et al. Jan 2020 B2
10543015 Walzman Jan 2020 B2
10543115 Franano et al. Jan 2020 B2
10548607 Walzman Feb 2020 B2
10561411 Cole et al. Feb 2020 B1
10561441 Walzman Feb 2020 B2
10603070 Walzman Mar 2020 B2
10610231 Marchand et al. Apr 2020 B2
10617428 Walzman Apr 2020 B2
10653403 Hebert et al. May 2020 B2
10716549 Keillor Jul 2020 B2
10716573 Connor Jul 2020 B2
10716574 Lorenzo et al. Jul 2020 B2
10729447 Shimizu et al. Aug 2020 B2
10743852 Moszner et al. Aug 2020 B2
10743884 Lorenzo Aug 2020 B2
10751065 Soto Del Valle et al. Aug 2020 B2
10751066 Lorenzo Aug 2020 B2
10772747 Fischer et al. Sep 2020 B2
10808341 Koppe Oct 2020 B2
10813645 Hewitt et al. Oct 2020 B2
10835257 Ferrera et al. Nov 2020 B2
10856879 Badruddin et al. Dec 2020 B2
10856880 Badruddin et al. Dec 2020 B1
10869672 Griffin Dec 2020 B2
10881413 Merritt et al. Jan 2021 B2
10888333 Kealey et al. Jan 2021 B2
10905430 Lorenzo et al. Feb 2021 B2
10925612 Wallace et al. Feb 2021 B2
10939914 Hewitt et al. Mar 2021 B2
10939915 Gorochow et al. Mar 2021 B2
10952739 Plaza et al. Mar 2021 B2
10959735 Morsi Mar 2021 B2
10980545 Bowman et al. Apr 2021 B2
11058430 Gorochow et al. Jul 2021 B2
20010041900 Callister Nov 2001 A1
20020082638 Porter et al. Jun 2002 A1
20020143349 Gifford, II et al. Oct 2002 A1
20020169473 Sepetka Nov 2002 A1
20020188314 Anderson et al. Dec 2002 A1
20030055451 Jones et al. Mar 2003 A1
20030120337 Tassel et al. Jun 2003 A1
20030171739 Murphy et al. Sep 2003 A1
20030176884 Berrada Sep 2003 A1
20030181927 Wallace Sep 2003 A1
20030195553 Wallace et al. Oct 2003 A1
20030220667 Van Der Burg Nov 2003 A1
20040034366 Burg et al. Feb 2004 A1
20040044391 Porter Mar 2004 A1
20040087998 Lee et al. May 2004 A1
20040098027 Teoh et al. May 2004 A1
20040127935 Tassel et al. Jul 2004 A1
20040133222 Tran et al. Aug 2004 A1
20040167597 Costantino Aug 2004 A1
20040172056 Guterman Sep 2004 A1
20040181253 Sepetka Sep 2004 A1
20040193246 Ferrera Sep 2004 A1
20040254594 Alfaro Dec 2004 A1
20040260332 Dubrul Dec 2004 A1
20050021016 Malecki et al. Jan 2005 A1
20050119684 Guterman Jun 2005 A1
20050251200 Porter Nov 2005 A1
20060052816 Bates et al. Mar 2006 A1
20060058735 Lesh Mar 2006 A1
20060064151 Guterman Mar 2006 A1
20060116709 Sepetka Jun 2006 A1
20060116713 Sepetka Jun 2006 A1
20060155323 Porter et al. Jul 2006 A1
20060155367 Hines Jul 2006 A1
20060167494 Suddaby Jul 2006 A1
20060206199 Churchwell et al. Sep 2006 A1
20070043391 Moszner et al. Feb 2007 A1
20070106311 Wallace et al. May 2007 A1
20070150045 Ferrera Jun 2007 A1
20070173928 Morsi Jul 2007 A1
20070198075 Levy Aug 2007 A1
20070203567 Levy Aug 2007 A1
20070208376 Meng Sep 2007 A1
20070225760 Moszner Sep 2007 A1
20070270902 Slazas Nov 2007 A1
20070288083 Hines Dec 2007 A1
20080045995 Guterman Feb 2008 A1
20080097401 Trapp Apr 2008 A1
20080097495 Feller, III et al. Apr 2008 A1
20080147100 Wallace Jun 2008 A1
20080221600 Dieck et al. Sep 2008 A1
20090082803 Adams Mar 2009 A1
20090099647 Glimsdale Apr 2009 A1
20090192455 Ferrera Jul 2009 A1
20090209855 Drilling et al. Aug 2009 A1
20090228029 Lee Sep 2009 A1
20090281557 Sander et al. Nov 2009 A1
20090297582 Meyer Dec 2009 A1
20090318941 Sepetka Dec 2009 A1
20100069948 Veznedaroglu et al. Mar 2010 A1
20100174309 Fulkerson Jul 2010 A1
20100217187 Fulkerson Aug 2010 A1
20100256600 Ferrera Oct 2010 A1
20100268204 Tieu et al. Oct 2010 A1
20100318097 Ferrera Dec 2010 A1
20110022149 Cox Jan 2011 A1
20110040319 Fulton, III Feb 2011 A1
20110046658 Connor et al. Feb 2011 A1
20110054519 Neuss Mar 2011 A1
20110082491 Sepetka Apr 2011 A1
20110152993 Marchand et al. Jun 2011 A1
20110160763 Ferrera et al. Jun 2011 A1
20110190797 Fulkerson Aug 2011 A1
20110202085 Loganathan Aug 2011 A1
20110264132 Strauss Oct 2011 A1
20110319926 Becking et al. Dec 2011 A1
20110319978 Schaffer Dec 2011 A1
20120016406 Ferrera Jan 2012 A1
20120041460 Ferrera Feb 2012 A1
20120041475 Ferrera Feb 2012 A1
20120071911 Sadasivan Mar 2012 A1
20120150147 Leynov Jun 2012 A1
20120165919 Cox Jun 2012 A1
20120172973 Deckard et al. Jul 2012 A1
20120271337 Figulla et al. Oct 2012 A1
20120277788 Cattaneo Nov 2012 A1
20120283768 Cox et al. Nov 2012 A1
20120330341 Becking et al. Dec 2012 A1
20120330347 Becking Dec 2012 A1
20130035628 Garrison Feb 2013 A1
20130035712 Theobald et al. Feb 2013 A1
20130066357 Aboytes et al. Mar 2013 A1
20130066360 Becking Mar 2013 A1
20130066413 Jin Mar 2013 A1
20130090682 Bachman et al. Apr 2013 A1
20130123830 Becking May 2013 A1
20130165967 Amin Jun 2013 A1
20130190800 Murphy Jul 2013 A1
20130197622 Mitra et al. Aug 2013 A1
20130245667 Marchand Sep 2013 A1
20130274862 Cox Oct 2013 A1
20130274866 Cox Oct 2013 A1
20130274868 Cox et al. Oct 2013 A1
20140005714 Quick et al. Jan 2014 A1
20140012307 Franano et al. Jan 2014 A1
20140012363 Franano et al. Jan 2014 A1
20140018838 Franano et al. Jan 2014 A1
20140052233 Cox Feb 2014 A1
20140163609 Solem Jun 2014 A1
20140172001 Becking et al. Jun 2014 A1
20140200607 Sepetka et al. Jul 2014 A1
20140257360 Keillor Sep 2014 A1
20140257374 Heisei et al. Sep 2014 A1
20140343602 Cox Nov 2014 A1
20140358178 Hewitt et al. Dec 2014 A1
20150105817 Marchand Apr 2015 A1
20150133990 Davidson May 2015 A1
20150150563 Marchand Jun 2015 A1
20150250628 Monstadt Sep 2015 A1
20150272589 Lorenzo Oct 2015 A1
20150351770 Fulton, III Dec 2015 A1
20150351775 Fulton, III Dec 2015 A1
20160106437 Van Der Burg Apr 2016 A1
20160113662 Kobayashi Apr 2016 A1
20160120551 Connor May 2016 A1
20160174991 Chin Jun 2016 A1
20160206321 Connor Jul 2016 A1
20160213380 O'Brien Jul 2016 A1
20160249934 Hewitt et al. Sep 2016 A1
20160249935 Hewitt et al. Sep 2016 A1
20160345979 Adams et al. Dec 2016 A1
20170128077 Hewitt et al. May 2017 A1
20170156733 Becking Jun 2017 A1
20170156734 Griffin Jun 2017 A1
20170172581 Bose Jun 2017 A1
20180125500 Connor May 2018 A1
20180140305 Connor May 2018 A1
20180193024 Walzman Jul 2018 A1
20180193043 Marchand Jul 2018 A1
20180206848 Walzman Jul 2018 A1
20180206851 Walzman Jul 2018 A1
20180214158 Walzman Aug 2018 A1
20180333248 Davidson Nov 2018 A1
20190008522 Lorenzo Jan 2019 A1
20190053810 Griffin Feb 2019 A1
20190059909 Griffin Feb 2019 A1
20190110796 Jayaraman Apr 2019 A1
20190183519 Imai Jun 2019 A1
20190209146 Hebert Jul 2019 A1
20190209178 Richter Jul 2019 A1
20190216467 Goyal Jul 2019 A1
20190223876 Badruddin Jul 2019 A1
20190223881 Hewitt Jul 2019 A1
20190231328 Hebert Aug 2019 A1
20190262002 Benjamin Aug 2019 A1
20190269414 Griffin Sep 2019 A1
20190274691 Sepetka Sep 2019 A1
20190336132 Warner Nov 2019 A1
20190343533 Costalat Nov 2019 A1
20190357914 Gorochow Nov 2019 A1
20190365472 Connor Dec 2019 A1
20190374228 Wallace Dec 2019 A1
20190380718 Morsi Dec 2019 A1
20190388108 Ferrera Dec 2019 A1
20200029973 Walzman Jan 2020 A1
20200038032 Rhee Feb 2020 A1
20200038035 Griffin Feb 2020 A1
20200054344 Connor Feb 2020 A1
20200060702 Davidson Feb 2020 A1
20200069313 Xu Mar 2020 A1
20200093499 Lorenzo Mar 2020 A1
20200100795 Connor Apr 2020 A1
20200113576 Gorochow Apr 2020 A1
20200138422 Hebert May 2020 A1
20200155333 Franano May 2020 A1
20200163784 Franano May 2020 A1
20200187952 Walsh Jun 2020 A1
20200187978 Walzman Jun 2020 A1
20200253766 Walzman Aug 2020 A1
20200268365 Hebert Aug 2020 A1
20200281603 Marchand Sep 2020 A1
20200289124 Rangwala Sep 2020 A1
20200289125 Dholakia Sep 2020 A1
20200289126 Hewitt Sep 2020 A1
20200305886 Soto Del Oct 2020 A1
20200323534 Shimizu Oct 2020 A1
20200337710 Lorenzo Oct 2020 A1
20200340154 Köppe Oct 2020 A1
20200345376 Fulton, III Nov 2020 A1
20200367894 Pereira Nov 2020 A1
20200367896 Zaidat Nov 2020 A1
20200367897 Wolfe Nov 2020 A1
20200367904 Becking Nov 2020 A1
20200375606 Lorenzo Dec 2020 A1
20200375607 Soto Del Valle Dec 2020 A1
20200390455 Nguyen Dec 2020 A1
20200397447 Lorenzo Dec 2020 A1
20200405347 Walzman Dec 2020 A1
20210007755 Lorenzo Jan 2021 A1
20210022765 Walzman Jan 2021 A1
20210045750 Wolfe Feb 2021 A1
20210068842 Griffin Mar 2021 A1
20210077116 Ferrera Mar 2021 A1
20210106337 Hewitt Apr 2021 A1
20210128160 Li May 2021 A1
20210128161 Nageswaran May 2021 A1
20210128162 Rhee May 2021 A1
20210128165 Pulugurtha May 2021 A1
20210128166 Kealey May 2021 A1
20210128167 Patel May 2021 A1
20210128168 Nguyen May 2021 A1
20210128169 Li May 2021 A1
20210129275 Nguyen May 2021 A1
20210145449 Gorochow May 2021 A1
20210153871 Griffin May 2021 A1
20210186518 Gorochow et al. Jun 2021 A1
20210251635 Soto Del Valle et al. Aug 2021 A1
Foreign Referenced Citations (193)
Number Date Country
2946078 Nov 2015 CA
102940514 Mar 2013 CN
103099652 May 2013 CN
104168843 Nov 2014 CN
104958087 Oct 2015 CN
204931771 Jan 2016 CN
102008028308 Apr 2009 DE
102008015781 Sep 2011 DE
102011102955 Dec 2012 DE
102009058132 Jul 2014 DE
202008018523 Apr 2015 DE
102013106031 Jul 2015 DE
102012107175 Aug 2015 DE
102012102844 Mar 2020 DE
102019121546 Feb 2021 DE
102019121554 Feb 2021 DE
0836450 Apr 1988 EP
0902704 Mar 1999 EP
1003422 May 2000 EP
1295563 Mar 2003 EP
1441649 Aug 2004 EP
1483009 Dec 2004 EP
1494619 Jan 2005 EP
1527753 May 2005 EP
1569565 Sep 2005 EP
1574169 Sep 2005 EP
1054635 Nov 2005 EP
1610666 Jan 2006 EP
1633275 Mar 2006 EP
1651117 May 2006 EP
1659988 May 2006 EP
1725185 Nov 2006 EP
1804719 Jul 2007 EP
1862122 Dec 2007 EP
1923005 May 2008 EP
1923019 May 2008 EP
2063791 Jun 2009 EP
2134263 Dec 2009 EP
2157937 Mar 2010 EP
2207500 Jul 2010 EP
2244666 Nov 2010 EP
2265193 Dec 2010 EP
2266465 Dec 2010 EP
2279023 Feb 2011 EP
2324775 May 2011 EP
2349024 Aug 2011 EP
2367482 Sep 2011 EP
2387951 Nov 2011 EP
2399524 Dec 2011 EP
2460476 Jun 2012 EP
2468349 Jun 2012 EP
2496299 Sep 2012 EP
2506808 Oct 2012 EP
2543345 Jan 2013 EP
2567663 Mar 2013 EP
2596754 May 2013 EP
2613709 Jul 2013 EP
2617386 Jul 2013 EP
2618709 Jul 2013 EP
2647343 Oct 2013 EP
2677944 Jan 2014 EP
2744412 Jun 2014 EP
2848211 Mar 2015 EP
2854704 Apr 2015 EP
2887887 Jul 2015 EP
2923674 Sep 2015 EP
2926744 Oct 2015 EP
2943152 Nov 2015 EP
2964105 Jan 2016 EP
3068337 Sep 2016 EP
3082619 Oct 2016 EP
3131515 Feb 2017 EP
3136986 Mar 2017 EP
3148481 Apr 2017 EP
3151904 Apr 2017 EP
3171793 May 2017 EP
3187117 Jul 2017 EP
3247285 Nov 2017 EP
3261703 Jan 2018 EP
1998686 Feb 2018 EP
2460477 Apr 2018 EP
3345553 Jul 2018 EP
2806825 Aug 2018 EP
2753246 Nov 2018 EP
3413808 Dec 2018 EP
3429479 Jan 2019 EP
3456271 Mar 2019 EP
3456272 Mar 2019 EP
3501429 Jun 2019 EP
2254505 Jul 2019 EP
3510945 Jul 2019 EP
3512459 Jul 2019 EP
3517055 Jul 2019 EP
2194885 Nov 2019 EP
3572010 Nov 2019 EP
3173037 Dec 2019 EP
3574851 Dec 2019 EP
3585275 Jan 2020 EP
3600068 Feb 2020 EP
3622901 Mar 2020 EP
3628242 Apr 2020 EP
3636173 Apr 2020 EP
2405820 Jun 2020 EP
3669800 Jun 2020 EP
3677192 Jul 2020 EP
3714812 Sep 2020 EP
3153114 Nov 2020 EP
3740138 Nov 2020 EP
3755276 Dec 2020 EP
3501428 Apr 2021 EP
3568088 Apr 2021 EP
3808284 Apr 2021 EP
3061647 Jun 2020 FR
248515 Jul 2019 IL
H02150481 Jun 1990 JP
H0447415 Apr 1992 JP
H08507011 Jul 1996 JP
2003-175113 Jun 2003 JP
2005028863 Feb 2005 JP
2005537092 Dec 2005 JP
2006509578 Mar 2006 JP
2010500187 Jan 2010 JP
2012-501793 Jan 2012 JP
2012030497 Feb 2012 JP
2013-027592 Feb 2013 JP
2013-509914 Mar 2013 JP
2013537069 Sep 2013 JP
2018131107 Oct 2018 RU
2019120682 Sep 2019 RU
2704539 Oct 2019 RU
2018145502 Jun 2020 RU
2018145543 Jun 2020 RU
2019110988 Oct 2020 RU
2019115837 Nov 2020 RU
2019116175 Nov 2020 RU
2019127900 Mar 2021 RU
2019129351 Mar 2021 RU
2019129526 Mar 2021 RU
WO 2006034149 Mar 2006 WO
WO 2006052322 May 2006 WO
WO 2007076480 Jul 2007 WO
WO 2007079402 Jul 2007 WO
WO 2008036156 Mar 2008 WO
WO 2008151204 Dec 2008 WO
WO 2009132045 Oct 2009 WO
WO 2009135166 Nov 2009 WO
WO 2010030991 Mar 2010 WO
WO 2010134914 Nov 2010 WO
WO 2011057002 May 2011 WO
WO 2012032030 Mar 2012 WO
WO 2012034135 Mar 2012 WO
WO 2012099704 Jul 2012 WO
WO 2012099909 Jul 2012 WO
WO 2012099910 Jul 2012 WO
WO 2012113554 Aug 2012 WO
WO 2012135037 Oct 2012 WO
WO 2012163880 Dec 2012 WO
WO 2013005195 Jan 2013 WO
WO 2013016618 Jan 2013 WO
WO 2013025711 Feb 2013 WO
WO 2013028579 Feb 2013 WO
WO 2013103888 Jul 2013 WO
WO 2013109309 Jul 2013 WO
WO 2013152327 Oct 2013 WO
WO 2013184595 Dec 2013 WO
WO 2014029835 Feb 2014 WO
WO 2015095538 Jun 2015 WO
WO 2015160721 Oct 2015 WO
WO 2015166013 Nov 2015 WO
WO 2015184075 Dec 2015 WO
WO 2015187196 Dec 2015 WO
WO 2016107357 Jul 2016 WO
WO 2016118420 Jul 2016 WO
WO 2016137997 Sep 2016 WO
WO 2017106567 Jun 2017 WO
WO 2017139702 Aug 2017 WO
WO 2017156275 Sep 2017 WO
WO 2017161283 Sep 2017 WO
WO 2018051187 Mar 2018 WO
WO 2018130624 Jul 2018 WO
WO 2018156833 Aug 2018 WO
WO 2018175221 Sep 2018 WO
WO 2019143755 Jul 2019 WO
WO 2019165360 Aug 2019 WO
WO 2020139544 Jul 2020 WO
WO 2020150023 Jul 2020 WO
WO 2020190620 Sep 2020 WO
WO 2020190630 Sep 2020 WO
WO 2020190639 Sep 2020 WO
WO 2020243039 Dec 2020 WO
WO 2021028160 Feb 2021 WO
WO 2021028161 Feb 2021 WO
WO 2021051110 Mar 2021 WO
Non-Patent Literature Citations (43)
Entry
US 9,034,010 B2, 05/2015, Amin (withdrawn)
Bosworth et al., “Gamma irradiation of electrospun poly(ϵ-caprolactone) fibers affects material properties but not cell response,” Journal of Polymer Science Part B: Polymer Physics, Apr. 2012, pp. 870-876.
CA Office Action in Canadian Appln. No. 2,946,078, dated May 26, 2021, 4 pages.
CN Office Action in Chinese Appln. No. 201580035663.X, dated Aug. 1, 2018, 27 pages (with English Translation).
CN Office Action in Chinese Appln. No. 201780024233.7, dated Apr. 22, 2021, 6 pages (with English translation).
CN Office Action in Chinese Appln. No. 201780024233.7, dated Jul. 9, 2020, 20 pages (with English Translation).
CN Office Action in Chinese Appln. No. 201780024233.7, dated Oct. 22, 2020, 17 pages (with English Translation).
EP Extended Search Report in European Appln. No. 19159876.2, dated Jun. 14, 2019, 9 pages.
EP Extended Search Report in European Appln. No. 20201759.6, dated Nov. 12, 2020, 12 pages.
EP Office Action in European Appln No. 16808631.2, dated Aug. 16, 2019, 8 pages.
Izadi et al., “Teflon hierarchical nanopillars with dry and wet adhesive properties,” Journal of Polymer Science Part B: Polymer Physics, Apr. 2012, pp. 846-851.
JP Office Action in Japanese Appln. No. 2018-529554, dated Nov. 30, 2020, 11 pages (with English translation).
JP Office Action in Japanese Appln. No. 2018-548075, dated Mar. 25, 2021, 8 pages (with English translation).
Ohta et al., “Size control of phase-separated liquid crystal droplets in a polymer matrix based on the phase diagram,” Journal of Polymer Science Part B: Polymer Physics, Apr. 2012, pp. 863-869.
Popov et al., “Interacting nanoparticles with functional surface groups,” Journal of Polymer Science Part B: Polymer Physics, Mar. 2012, pp. 852-862.
U.S. Appl. No. 14/699,188, filed Nov. 5, 2015.
U.S. Appl. No. 15/372,128, filed May 14, 2019.
U.S. Appl. No. 16/080,626, filed Aug. 28, 2018.
U.S. Appl. No. 16/172,157, filed Oct. 26, 2018.
U.S. Appl. No. 16/407,957, filed Sep. 5, 2019.
U.S. Appl. No. 16/590,821, filed Oct. 2, 2019.
U.S. Appl. No. 16/640,142, filed Feb. 19, 2020.
U.S. Appl. No. 16/952,756, filed Nov. 19, 2020.
JP Office Action in Japanese Application No. 2018-529554, dated Jul. 12, 2021, 6 pages (with English translation).
JP Office Action in Japanese Application No. 2018-529554, dated Sep. 15, 2020, 6 pages (with English translation).
JP Office Action in Japanese Application No. 2019-145966, dated Sep. 1, 2020, 6pages (with English translation).
PCT International Preliminary Report on Patentability in International Application No. PCT/EP2016/080152, dated Jun. 12, 2018, 10 pages.
PCT International Preliminary Report on Patentability in International Application No. PCT/EP2017/055765, dated Sep. 11, 2018, 9 pages.
PCT International Written Opinion in International Application No. PCT/EP2021/054103, dated Aug. 26, 2021, 4 pages.
Altes et al., “Creation of Saccular Aneurysms in the Rabbit: A Model Suitable for Testing Endovascular Devices,” AJR Am J Roentgenol. 2000, 174(2):349-354.
Blackshear et al., “Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation,” Ann. Thorac. Surg., Feb. 1996, 61(2):755-9.
CN Office Action in Chinese Appln. No. 201780024233.7, dated Jul. 9, 2020, 15 pages (with English Translation).
Gottlieb et al., “Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice?” Arch. Intern. Med., Sep. 1994, 154(17):I945-53.
JP Office Action in Japanese Appln. 2017-508761, dated Nov. 27, 2018, 4 pages (English translation).
JP Office Action in Japanese Appln. No. 2017-508761, dated Mar. 19, 2019, 3 pages (English translation).
PCT Form ISA/206—Invitation To Pay Additional Fees in International Appln. PCT/EP2016/080152, dated Feb. 24, 2017, 9 pages.
PCT International Preliminary Report on Patentability in International Application No. PCT/EP2015/059429, dated Jul. 13, 2016, 11 pages.
PCT International Preliminary Report on Patentability in International Appln. No. PCT/EP2019/072576, dated Feb. 25, 2020, 12 pages.
PCT International Search Report and Written Opinion in International Application No. PCT/EP20I6/080152, dated Jun. 16, 2017, 8 pages.
PCT International Search Report and Written Opinion in International Appln. No. PCT/EP2018/072576, dated Nov. 21, 2018, 20 pages.
PCT International Search Report and Written Opinion in International Appln. PCT/EP2015/059429, dated Jul. 6, 2015, 5 pages.
PCT International Search Report in International Appln. PCT/EP2017/055765, dated Apr. 18, 2017, 5 pages.
Schaffer. “Biocompatible Wire.” Advanced Materials & Processes, Oct. 2002, pp. 51-54.
Related Publications (1)
Number Date Country
20210259719 A1 Aug 2021 US